Trial Profile
A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Ipsen
- 07 Oct 2015 New trial record